Clinical Report: The Role of GLA in the Progression of ESCC
Overview
This study identifies α-Galactosidase A (GLA) as a significantly upregulated gene in esophageal squamous cell carcinoma (ESCC) with diagnostic relevance. GLA knockdown enhances chemosensitivity to gemcitabine and cisplatin.
Background
Esophageal squamous cell carcinoma (ESCC) is a leading cause of cancer-related mortality, particularly in regions like China. Chemoresistance remains a significant barrier to effective treatment.
Data Highlights
Method
Findings
GLA Expression
Significantly upregulated in ESCC across multiple datasets
Knockdown Effects
Suppressed proliferation, colony formation, and migration
Chemosensitivity
Increased sensitivity to gemcitabine and cisplatin with GLA knockdown
Combination Therapy
Migalastat combined with chemotherapy enhanced cytotoxicity
Key Findings
GLA is upregulated in ESCC and associated with poor prognosis.
High GLA expression correlates with DNA damage repair and chemoresistance.
GLA knockdown significantly reduces cell proliferation and migration in ESCC cell lines.
Combining Migalastat with gemcitabine or cisplatin shows synergistic effects.
GLA serves as a potential diagnostic marker for ESCC.
Clinical Implications
Further investigation into GLA's role in ESCC is warranted.
Conclusion
GLA is a novel oncogenic factor in ESCC, influencing tumor progression and response to chemotherapy.
